Form 4: ENDRA CFO Acquires 13,461 Restricted Stock Units

ENDRA Life Sciences Inc.'s Chief Financial Officer, Richard Jacroux, acquired 13,461 restricted stock units, increasing his beneficial ownership.

Summary

• Richard Jacroux, Chief Financial Officer of ENDRA Life Sciences Inc. (NDRA), acquired 13,461 shares of Common Stock.
• These shares represent Restricted Stock Units (RSUs) and were acquired at a price of $0.
• Following this transaction, Jacroux beneficially owns a total of 33,461 shares of Common Stock, which includes unvested RSUs.
• The newly acquired RSUs are scheduled to vest in full on June 11, 2026.
• The transaction date for this acquisition was March 2, 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as an insider increasing their stake, even through equity awards, generally indicates confidence in the company's future prospects and aligns management incentives.

Positives

• The Chief Financial Officer, Richard Jacroux, increased his beneficial ownership in ENDRA Life Sciences Inc. by acquiring 13,461 Restricted Stock Units.
• This acquisition, typical for RSU grants at a $0 price, aligns management's interests with those of shareholders, potentially signaling confidence in the company's future.

Risks

• The value of the acquired Restricted Stock Units is directly tied to the future performance of ENDRA Life Sciences Inc.'s common stock, exposing the holder to market fluctuations.

Future Outlook

The future outlook, as indicated by this filing, includes the full vesting of the acquired Restricted Stock Units on June 11, 2026, which suggests a continued long-term alignment of the CFO's interests with the company's performance.

Industry Context

StockSavvy.ai notes that insider acquisitions, particularly through equity awards like Restricted Stock Units, are a common and standard mechanism for executive compensation. This practice aims to align management incentives with shareholder value creation and is widely observed across the life sciences industry for retaining and motivating key executives.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) at a $0 acquisition price is a standard form of executive compensation across various industries, including the life sciences sector.
• The specified vesting schedule (full vesting on June 11, 2026) is a common retention strategy, similar to equity award structures seen in larger pharmaceutical companies like Pfizer or emerging biotech firms, designed to incentivize long-term commitment.
• An increase in beneficial ownership by a Chief Financial Officer is generally viewed as a positive signal of confidence in the company's future prospects, consistent with trends observed among executives at comparable small-cap biotechnology companies.

Stakeholder Impact

• Shareholders: The increase in the CFO's beneficial ownership may be perceived as a positive indicator of management's commitment and confidence in the company's future performance.
• Employees: Standard equity compensation practices, such as RSU grants, can contribute to executive retention and motivation, potentially fostering a stable leadership environment.

Next Steps

• The 13,461 Restricted Stock Units acquired by the CFO are scheduled to vest in full on June 11, 2026.

Key Dates

Recommendation

The acquisition of Restricted Stock Units by the CFO, while a positive indicator of management alignment and confidence, is a routine compensation event. It does not provide sufficient new fundamental information to significantly alter a broader investment thesis, thus supporting a 'hold' recommendation for existing investors or a neutral stance for potential new investors awaiting more comprehensive financial updates.

Keywords

ENDRA Life Sciences, NDRA, Form 4, Insider Transaction, Restricted Stock Units, RSU, Richard Jacroux, CFO, Beneficial Ownership